Comparative Study of Perioperative Cardiac Injury in Patients With Functional Adrenal Tumors

September 11, 2025 updated by: Peking University First Hospital

Dynamic Monitoring and Comparative Study of Perioperative Cardiac Injury in Patients With Functional Adrenal Tumors

The main goal of this study is to follow patients with functional adrenal tumors during the time before and after their surgery.

The main questions it aims to answer are:

  • What heart and blood pressure changes do patients with different types of adrenal tumors have before surgery?
  • What factors affect how the heart and blood pressure recover after surgery?
  • Do the heart and blood pressure conditions before surgery influence recovery and the risk of heart or brain problems after surgery?

Patients will have heart ultrasound checks and health monitoring before and after surgery. The results will help doctors choose the right medicines before surgery, better understand possible risks during the operation, and make safer treatment plans for patients with functional adrenal tumors.

Study Overview

Status

Enrolling by invitation

Conditions

Study Type

Observational

Enrollment (Estimated)

150

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • China
      • Beijing, China
        • Peking University First Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

The study population consists of patients with functional adrenal tumors who are hospitalized and/or seen in the outpatient clinic of the Department of Urology at Peking University First Hospital.

Description

Inclusion Criteria:

  • Patients diagnosed in the Department of Urology, Peking University First Hospital with pheochromocytoma and paraganglioma (PPGL), primary aldosteronism (PA), or Cushing syndrome (CS);
  • Written informed consent obtained.

Exclusion Criteria:

  • Patients with PPGL, PA, or CS who receive medication or conservative treatment and are not eligible for surgical resection;
  • Patients with communication disorders or severe physical impairments such as aphasia, or visual/hearing disabilities;
  • Patients with severe mental illness who cannot cooperate with the study;
  • Pregnant women or patients otherwise deemed unsuitable for participation by the investigators.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
primary aldosteronism
Cushing s Syndrome
Pheochromocytoma/Paraganglioma (PPGL)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Recovery of cardiac function after adrenal surgery
Time Frame: from enrollment to 4,24,48 weeks after surgery
global longitudinal stress
from enrollment to 4,24,48 weeks after surgery

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Recovery of blood pressure after adrenal surgery
Time Frame: from enrollment to 4,24,48 weeks after surgery
Decrease in 24h average blood pressure
from enrollment to 4,24,48 weeks after surgery

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Peking University First Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 19, 2024

Primary Completion (Actual)

November 17, 2024

Study Completion (Estimated)

May 29, 2026

Study Registration Dates

First Submitted

September 11, 2025

First Submitted That Met QC Criteria

September 11, 2025

First Posted (Estimated)

September 19, 2025

Study Record Updates

Last Update Posted (Estimated)

September 19, 2025

Last Update Submitted That Met QC Criteria

September 11, 2025

Last Verified

September 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2024yan411-002

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Data cannot be shared, because data from this study may contain potentially or sensitive patient information.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Primary Aldosteronism

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Georgia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe